Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca’s Ambitious Plans For Alexion

New HQ In Kendall Square

Executive Summary

The UK major’s CEO, Pascal Soriot, said the setting-up of a new R&D hub in Cambridge, MA, which will also serve as the new corporate headquarters for Alexion, is "a milestone moment" for the rare diseases unit.

You may also be interested in...



Analysts Admire Argenx's Vyvgart Launch

The generalized myasthenia gravis-approved drug passed the $20m mark in sales for the first quarter, comfortably surpassing analyst estimates.

AstraZeneca Clears Ultomiris Overhang With Patent Settlement

The company will pay Chugai $775m to settle a patent dispute related to the complement 5 inhibitor Ultomiris, which it acquired from Alexion.

Nearly Nine Years In The Making, AstraZeneca Finally Unveils New Cambridge R&D Hub

After an expensive and protracted construction, AstraZeneca hopes its Cambridge research center will help foster collaboration and extend its run of R&D success.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146310

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel